zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
sporanox 100 mg kapseli, kova
janssen-cilag oy - itraconazole - kapseli, kova - 100 mg - itrakonatsoli
irinotecan sun 1.5 mg/ml infuusioneste, liuos
sun pharmaceutical industries europe b.v. - irinotecan hydrochloride trihydric - infuusioneste, liuos - 1.5 mg/ml - irinotekaani
dormicum 15 mg tabletti, kalvopäällysteinen
cheplapharm arzneimittel gmbh - midazolam maleate - tabletti, kalvopäällysteinen - 15 mg - midatsolaami
dormicum 7.5 mg tabletti, kalvopäällysteinen
cheplapharm arzneimittel gmbh - midazolam maleate - tabletti, kalvopäällysteinen - 7.5 mg - midatsolaami
prograf 5 mg/ml infuusiokonsentraatti, liuosta varten
astellas pharma a/s - tacrolimus - infuusiokonsentraatti, liuosta varten - 5 mg/ml - takrolimuusi
fentanyl sandoz 37.5 mikrog/tunti depotlaastari
sandoz a/s sandoz a/s - fentanylum - depotlaastari - 37.5 mikrog/tunti - fentanyyli
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karsinooma, squamous cell - antineoplastiset aineet - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
sporanox 10 mg/ml oraaliliuos
janssen-cilag oy - itraconazole - oraaliliuos - 10 mg/ml - itrakonatsoli
irinotecan pfizer 20 mg/ml infuusiokonsentraatti, liuosta varten
pfizer oy - irinotecan hydrochloride trihydric - infuusiokonsentraatti, liuosta varten - 20 mg/ml - irinotekaani